Toby Maher, MD, PhD, discusses how idiopathic pulmonary fibrosis (IPF) is a specific form of interstitial lung disease characterized by progressive lung scarring, which leads to significant ...
The FDA has approved Boehringer Ingelheim’s Jascayd (nerandomilast) as an oral treatment option for idiopathic pulmonary fibrosis (IPF) in adult patients.
The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis ...
Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects. In a phase 2 trial involving patients with ...
Delayed IPF diagnosis often results in significant lung function impairment, impacting patient outcomes and increasing hospitalization rates. Antifibrotic therapies, nintedanib and pirfenidone, are ...
Nerandomilast reduces the expression of pro-fibrotic growth factors and inflammatory cytokines, commonly overexpressed in IPF.
The Chosun Ilbo on MSN
Jaksade Approved: First New Pulmonary Fibrosis Drug in a Decade
A new drug to alleviate idiopathic pulmonary fibrosis, a condition where the lungs harden and make breathing difficult, has ...
In the Phase III FIBRONEER-IPF study, Jascayd demonstrated significant lung capacity improvements over placebo.
In a phase 3 study, nerandomilast administered at 18 mg or 9 mg twice daily slowed the progression of pulmonary fibrosis in adults with progressive pulmonary fibrosis. In a previous study, ...
CAL101 is a first-in-class monoclonal antibody targeting S100A4, a damage-associated molecular pattern (DAMP) protein associated with serious and life-threatening fibrotic disorders Phase 2 AURORA ...
The FDA granted approval to nerandomilast, now Jascayd, for treating adults with idiopathic pulmonary fibrosis, marking the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback